Medtech Industry Faces Structural Shifts in 2026

News Summary

Medical technology companies are navigating a period of accelerated change as pricing pressures, supply chain volatility, and technological advances reshape the industry. A report by Clarivate, “Medtech Trends to Watch in 2026,” identifies five key trends that will influence market strategies over the coming year.

Lead Paragraph

The global medtech industry is entering a transformative phase, driven by structural forces across pricing, care delivery, supply chains, and technology. According to Clarivate’s latest analysis, companies must adapt to a landscape where volume-based procurement in China, the migration of procedures to outpatient settings, trade disruptions, GLP-1 therapy adoption, and platform-based competition are redefining how value is created and delivered.

Background

The medtech sector has long been characterized by innovation and high-growth markets. However, major shifts in healthcare policy, global trade dynamics, and consumer behavior are forcing manufacturers to reassess their strategies. The Clarivate report, published in 2026, synthesizes proprietary data and expert insights to highlight the most consequential trends for the industry.

Main Reporting

#### 1. China’s Volume-Based Procurement Expands
Mainland China’s national volume-based procurement (VBP) program has evolved from a cost-containment tool into a powerful market structuring mechanism. The latest round introduces sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational corporations, VBP now influences pricing expectations and competitive positioning not only in China but also in other global markets, as international buyers benchmark against these price levels.

#### 2. Shift to Outpatient and Ambulatory Surgical Centers
The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list. This change allows higher-acuity procedures, such as cardiac ablation, to be performed in lower-cost outpatient settings when clinically appropriate. The trend builds on earlier shifts in orthopedics and general surgery, making ASCs central to procedure growth strategies.

#### 3. Supply Chain Resilience and Tariff Pressures
Global trade tensions, tariff exposure, and fluctuating material costs are challenging traditional assumptions about device manufacturing. In response, companies are diversifying sourcing, re-evaluating business strategies, and establishing multi-region production footprints. Larger manufacturers are leveraging scale and technology investments to buffer against volatility, which could reshape competitive dynamics within the industry.

#### 4. Impact of GLP-1 Therapies on Patient Behavior
The rapid uptake of glucagon-like peptide-1 (GLP-1) receptor agonists is altering how patients and clinicians approach weight management and related comorbidities. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1 therapies have changed referral patterns and are influencing demand across adjacent medtech categories, including diabetes care, sleep apnea, and cardiovascular monitoring.

#### 5. Platform-Based Competition via Enabling Technologies
Robotics, imaging, navigation, and digital workflow software are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care. Companies are investing in platform architectures that anchor entire service lines and unlock data-driven value. Emerging open-platform systems are also creating new competitive dynamics by expanding flexibility and interoperability.

International Context

These trends reflect broader global forces: China’s evolving role in healthcare pricing, U.S. policy shifts toward value-based care, supply chain globalisation, and the convergence of medical devices with digital technology. In Europe and other regions, similar pricing and outpatient pressures are emerging, while trade uncertainties prompt worldwide rethinking of manufacturing footprints.

Verified Analysis

The Clarivate report provides a structured overview of medtech trends backed by proprietary data, but the actual impact will depend on regulatory implementation and market adoption. For instance, VBP expansions in China may accelerate domestic innovation but could reduce margins for foreign entrants. The ASC shift is expected to improve cost efficiency but might require adjustments in device design and training. Similarly, GLP-1 therapies could reduce demand for some surgical procedures while expanding opportunities in adjacent monitoring markets.

Companies that proactively embrace platform ecosystems and supply chain flexibility are likely to gain a competitive edge. However, the pace of change will vary by therapy area and geographic market, requiring careful regional strategies.

Future Developments

Over the next two to five years, these trends are expected to deepen. China may further refine VBP policies, pushing multinationals to localize production or collaborate with domestic players. The migration of procedures to ASCs will likely continue, prompting more outpatient-friendly devices and digital tools. Supply chains will become more regionally diversified, with increased automation and near-sourcing. GLP-1 indications are expected to expand, creating ripple effects across multiple device markets. Meanwhile, enabling technologies will increasingly integrate into standard care, making platform-based competition the norm.

Conclusion

Medtech companies face a complex environment where pricing, care delivery, and technology are undergoing simultaneous transformation. Success will depend on strategic agility, investment in enabling technologies, and the ability to navigate shifting regulatory and trade landscapes. The industry’s future will be defined by adaptability and a global perspective.

Key Takeaways

• China’s VBP program is reshaping global medtech pricing and market access.
• Outpatient and ambulatory surgical centers are becoming central to procedure strategies.
• Supply chain resilience is now a strategic imperative for manufacturers.
• GLP-1 therapies are altering clinical pathways and device demand.
• Platform-based competition, driven by enabling technologies, is redefining value delivery.

Sources

• Clarivate: Medtech Trends to Watch in 2026